Skip to main content

Advertisement

SpringerLink
Log in

Efficacy and Safety of Propiverine Hydrochloride for Overactive Bladder in Adult: a Systematic Review and Meta-analysis

  • Review Article
  • Published:
Indian Journal of Surgery Aims and scope Submit manuscript

Abstract

We carried out a systematic review and meta-analysis to assess the efficacy and safety of propiverine for treating overactive bladder (OAB) in adult. A literature review was performed to identify all published randomized placebo-controlled trials (RCT) of propiverine for the treatment of OAB. The search included the following databases: PUBMED and EMBASE. The reference lists of retrieved studies were also investigated. A systematic review and meta-analysis were conducted. Ten publications involving nine different RCTs were used in the analysis. We found that propiverine was effective in treating OAB in our meta-analysis. The decrease in number of micturitions/24 h (P < 0.00001, the mean decrease was from 1.80 to 2.57) indicated that propiverine was more effective than the placebo. Propiverine also decrease the number of urgency, urgency incontinence, and nocturia and increase urine volume. However, the incidence of difficulty in voiding was higher with propiverine therapy compared with the placebo (P = 0.05, the mean percentage range from 0.34 to 4.93 %). The decrease of total international prostate symptom score (IPSS) (P < 0.0001, the mean decrease was from 12.5 to 16.1) indicated that propiverine add a1-adrenoceptor antagonist was more effective in decreasing the lower urinary tract symptom (LUTS). The combination therapy also decreases the voiding symptom and storage symptom scores and increases maximum flow rate. This meta-analysis shows that propiverine is a safe and effective treatment for OAB. The major adverse event associated with propiverine treatment was difficulty in voiding. Propiverine add a1-adrenoceptor antagonist was more effective in terms of decreasing difficulty in voiding.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U et al (2002) The standardisation of terminology of lower urinary tract function: report from the standardisation sub-committee of the international continence society. Neurourol Urodyn 21:167–178

    Article  PubMed  Google Scholar 

  2. Milsom I, Kaplan SA, Coyne KS, Sexton CC, Kopp ZS (2012) Effect of bothersome overactive bladder symptoms on health-related quality of life, anxiety, depression, and treatment seeking in the United States: results from EpiLUTS. Urology 80(1):90–96

    Article  PubMed  Google Scholar 

  3. Zhu HL, Brain KL, Aishima M, Shibata A, Young JS, Sueishi K et al (2008) Actions of two main metabolites of propiverine (M-1 and M-2) on voltage-dependent L-type Ca2+ currents and Ca2+ transients in murine urinary bladder myocytes. J Pharmacol Exp Ther 324(1):118–127

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Yoshida M, Homma Y, Inadome A, Yono M, Seshita H, Miyamoto Y et al (2001) Age-related changes in cholinergic and purinergic neurotransmission in human isolated bladder smooth muscles. Exp Gerontol 36:99–109

    Article  CAS  PubMed  Google Scholar 

  5. Yono M, Yoshida M, Wada Y, Kikukawa H, Takahashi W, Inadome A et al (1999) Pharmacological effects of tolterodine on human isolated urinary bladder. Eur J Pharmacol 368:223–230

    Article  CAS  PubMed  Google Scholar 

  6. Gotoh M, Yokoyama O, Nishizawa O (2011) Propiverine hydrochloride in Japanese patients with overactive bladder: a randomized, double-blind, placebo-controlled trial. Int J Urol 18:365–373

    Article  CAS  PubMed  Google Scholar 

  7. Higgins JPT, Green S, editors (2011) Cochrane handbook for systematic reviews of interventions, v.5.1 [updated March 2011]. Cochrane Collaboration Web site. http://www.cochrane-handbook.org/

  8. Yamaguchi O, Marui E, Kakizaki H, Itoh N, Yokota T, Okada H et al (2007) Japanese Solifenacin Study Group: randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder. BJU Int 100(3):579–587

    Article  CAS  PubMed  Google Scholar 

  9. Yamaguchi O, Uchida E, Higo N, Minami H, Kobayashi S, Sato H (2014) Efficacy and safety of once-daily oxybutynin patch versus placebo and propiverine in Japanese patients with overactive bladder: a randomized double-blind trial. Int J Urol 21(6):586–593

    Article  CAS  PubMed  Google Scholar 

  10. Homma Y, Yamaguchi O (2009) A randomized, double-blind, placebo- and propiverine-controlled trial of the novel antimuscarinic agent imidafenacin in Japanese patients with overactive bladder. Int J Urol 16(5):499–506

    Article  CAS  PubMed  Google Scholar 

  11. Lee KS, Lee HW, Choo MS, Paick JS, Lee JG, Seo JT et al (2010) Urinary urgency outcomes after propiverine treatment for an overactive bladder: the ‘Propiverine study on overactive bladder including urgency data. BJU Int 105(11):1565–1570

    Article  CAS  PubMed  Google Scholar 

  12. Lee KS, Choo MS, Kim DY, Kim JC, Kim HJ, Min KS et al (2005) Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: a prospective, randomized, controlled multicenter study. J Urol 174(4 Pt 1):1334–1338

    Article  CAS  PubMed  Google Scholar 

  13. Yokoyama T, Uematsu K, Watanabe T, Sasaki K, Kumon H, Nagai A (2009) Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study. Scand J Urol Nephrol 43(4):307–314

    Article  CAS  PubMed  Google Scholar 

  14. Bae JH, Kim SO, Yoo ES, Moon KH, Kyung YS, Kim HJ (2011) Efficacy and safety of low-dose propiverine in patients with lower urinary tract symptoms/benign prostatic hyperplasia with storage symptoms: a prospective, randomized, single-blinded and multicenter clinical trial. Korean J Urol 52(4):274–278

    Article  PubMed  PubMed Central  Google Scholar 

  15. Sener NC, Ozturk U, Goktug HN, Gucuk A, Nalbant I, Yesil S et al (2013) Efficacy and safety of propiverine and terazosine combination for one year in male patients with luts and detrusor overactivity. Int Braz J Urol 39(4):513–518

    Article  PubMed  Google Scholar 

  16. Madersbacher H, Mürtz G (2001) Efficacy, tolerability and safety profile of propiverine in the treatment of the overactive bladder (non-neurogenic and neurogenic). World J Urol 19(5):324–335

    Article  CAS  PubMed  Google Scholar 

  17. Engström G, Henningsohn L, Walker-Engström ML, Leppert J (2006) Impact on quality of life of different lower urinary tract symptoms in men measured by means of the SF 36 questionnaire. Scand J Urol Nephrol 40:485–494

    Article  PubMed  Google Scholar 

  18. Sountoulides P, van Dijk MM, Wijkstra H, de la Rosette JJ, Michel MC (2010) Role of voiding and storage symptoms for the quality of life before and after treatment in men with voiding dysfunction. World J Urol 28:3–8

    Article  PubMed  PubMed Central  Google Scholar 

  19. Chapple CR, Carter P, Christmas TJ, Kirby RS, Bryan J, Milroy EJ et al (1994) A three month double-blind study of doxazosin as treatment for benign prostatic bladder outlet obstruction. Br J Urol 74(1):50–56

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of Interest Statement

The authors had no conflicts of interest to declare in relation to this article.

Author information

Authors and Affiliations

  1. Department of Urology, Beijing Tian Tan Hospital, Capital Medical University, No. 6 Tiantan Xi Li, Dongcheng District, Beijing, 100050, China

    Wei Huang, Huantao Zong, Xin Zhou, Tao Wang & Yong Zhang

Authors
  1. Wei Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Huantao Zong
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xin Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tao Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yong Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yong Zhang.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Huang, W., Zong, H., Zhou, X. et al. Efficacy and Safety of Propiverine Hydrochloride for Overactive Bladder in Adult: a Systematic Review and Meta-analysis. Indian J Surg 77 (Suppl 3), 1369–1377 (2015). https://doi.org/10.1007/s12262-015-1264-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12262-015-1264-1

Keywords

Search

Navigation